Sep 22, 2021 / 12:00PM GMT
Operator
Hello, and welcome to the Incyte Opzelura Approval Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Christine Chiou. Please go ahead.
Christine Chiou - Incyte Corporation - Head of IR
Thank you, Kevin. Good morning, and welcome to Incyte's Conference Call and Webcast to discuss the FDA approval of Opzelura, which was announced yesterday. I have the pleasure of introducing Dr. Larry Eichenfield from the University of San Diego. He is Professor of Dermatology and Pediatrics, Vice Chair of the Department of Dermatology and Chief of Pediatric and Adolescent Dermatology at UC San Diego School of Medicine and Rady Children's Hospital, San Diego. He has also served as an investigator on some of our studies.
Speaking on the call today from Incyte are Herve; Jim Lee, our Head of Development and Inflammation and Autoimmunity; and Todd Edwards, our Dermatology Business Unit Head. Barry and Christiana will also participate in the Q&A session.
Before we
Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Transcript
Sep 22, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers